MINNEAPOLIS & VIENNA, Austria--(BUSINESS WIRE)--In conjunction with the European Society of Cardiology Congress being held this week in Vienna, Austria, Medtronic, Inc. (NYSE:MDT) announced results from several clinical studies regarding the treatment and management of heart failure patients, as well as post-myocardial infarction (MI) patient risk stratification. The clinical evidence presentations follow closely on CE Mark receipt for the Medtronic CareLink® Network and its capabilities of remotely and wirelessly monitoring heart failure patients with implantable cardiac devices in 14 countries around the world.
